{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:36:19Z","timestamp":1793568979877,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Medical Science and Technology Innovation Award Project of Henan Academy of Innovations in Medical Science","award":["CXIL202404"],"award-info":[{"award-number":["CXIL202404"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11904-7","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T18:29:38Z","timestamp":1755109778000},"page":"1379-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-6082","authenticated-orcid":false,"given":"Yiyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-0010","authenticated-orcid":false,"given":"Zihao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-1335","authenticated-orcid":false,"given":"Jianbo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"11904_CR1","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R (2020) Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci 21:4012","journal-title":"Int J Mol Sci"},{"key":"11904_CR2","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21834:10.3322\/caac.21834","DOI":"10.3322\/caac.21834:10.3322\/caac.21834"},{"key":"11904_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L et al (2021) Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 14:156","journal-title":"J Hematol Oncol"},{"key":"11904_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690\u2013714","journal-title":"Cancer Cell"},{"key":"11904_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijsu.2018.01.008","volume":"51","author":"F Coccolini","year":"2018","unstructured":"Coccolini F, Nardi M, Montori G et al (2018) Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg 51:120\u2013127","journal-title":"Int J Surg"},{"key":"11904_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","volume":"11","author":"D Salas-Benito","year":"2021","unstructured":"Salas-Benito D, P\u00e9rez-Gracia JL, Ponz-Sarvis\u00e9 M et al (2021) Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov 11:1353\u20131367","journal-title":"Cancer Discov"},{"key":"11904_CR7","doi-asserted-by":"publisher","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","volume":"31","author":"M Moehler","year":"2020","unstructured":"Moehler M, Shitara K, Garrido M et al (2020) LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1\u2009L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol 31:S1191","journal-title":"Ann Oncol"},{"key":"11904_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207\u2013212","journal-title":"Curr Opin Immunol"},{"key":"11904_CR9","doi-asserted-by":"publisher","first-page":"M113","DOI":"10.1136\/mp.48.3.M113","volume":"48","author":"W Ross","year":"1995","unstructured":"Ross W, Hall PA (1995) Ki67: from antibody to molecule to understanding? Clin Mol Pathol 48:M113\u2013M117","journal-title":"Clin Mol Pathol"},{"key":"11904_CR10","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3748\/wjg.v29.i10.1602","volume":"29","author":"L-T Mao","year":"2023","unstructured":"Mao L-T, Chen W-C, Lu J-Y et al (2023) Quantitative parameters in novel spectral computed tomography: assessment of Ki-67 expression in patients with gastric adenocarcinoma. World J Gastroenterol 29:1602\u20131613","journal-title":"World J Gastroenterol"},{"key":"11904_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10120-023-01429-7","volume":"26","author":"M Chivu-Economescu","year":"2023","unstructured":"Chivu-Economescu M, Herlea V, Dima S et al (2023) Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients. Gastric Cancer 26:934\u2013946","journal-title":"Gastric Cancer"},{"key":"11904_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","volume":"25","author":"CS Fuchs","year":"2022","unstructured":"Fuchs CS, \u00d6zg\u00fcro\u011flu M, Bang Y-J et al (2022) Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25:197\u2013206","journal-title":"Gastric Cancer"},{"key":"11904_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3727\/096504016X14719078133564","volume":"25","author":"S Li","year":"2017","unstructured":"Li S, Li B, Wang J et al (2017) Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncol Res 25:93\u201397","journal-title":"Oncol Res"},{"key":"11904_CR14","doi-asserted-by":"publisher","first-page":"111052","DOI":"10.1016\/j.ejrad.2023.111052","volume":"167","author":"M Du","year":"2023","unstructured":"Du M, Wang X, Zhuang S et al (2023) Quantitative parameters in novel spectral computed tomography for assessing gastric cancer and cell proliferation. Eur J Radiol 167:111052","journal-title":"Eur J Radiol"},{"key":"11904_CR15","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551","journal-title":"Lancet Oncol"},{"key":"11904_CR16","doi-asserted-by":"publisher","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D et al (2017) PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One 12:e0182692","journal-title":"PLoS One"},{"key":"11904_CR17","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.7150\/jca.30074","volume":"10","author":"D-D Xiong","year":"2019","unstructured":"Xiong D-D, Zeng C-M, Jiang L, Luo D-Z, Chen G (2019) Ki-67\/MKI67 as a predictive biomarker for clinical outcome in gastric cancer patients: an updated meta-analysis and systematic review involving 53 studies and 7078 patients. J Cancer 10:5339\u20135354","journal-title":"J Cancer"},{"key":"11904_CR18","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1007\/s00330-023-09464-9","volume":"33","author":"J Li","year":"2023","unstructured":"Li J, Xu S, Wang Y et al (2023) Spectral CT-based nomogram for preoperative prediction of perineural invasion in locally advanced gastric cancer: a prospective study. Eur Radiol 33:5172\u20135183","journal-title":"Eur Radiol"},{"key":"11904_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.crad.2015.06.083","volume":"70","author":"L Tang","year":"2015","unstructured":"Tang L, Li ZY, Li ZW et al (2015) Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol 70:1198\u20131204","journal-title":"Clin Radiol"},{"key":"11904_CR20","doi-asserted-by":"publisher","first-page":"111072","DOI":"10.1016\/j.ejrad.2023.111072","volume":"167","author":"X Tan","year":"2023","unstructured":"Tan X, Yang X, Hu S, Chen X, Sun Z (2023) A nomogram for predicting postoperative complications based on tumor spectral CT parameters and visceral fat area in gastric cancer patients. Eur J Radiol 167:111072","journal-title":"Eur J Radiol"},{"key":"11904_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13244-024-01844-z","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yuan M, Zhao Z et al (2024) A quantitative model using multi-parameters in dual-energy CT to preoperatively predict serosal invasion in locally advanced gastric cancer. Insights Imaging 15:264","journal-title":"Insights Imaging"},{"key":"11904_CR22","doi-asserted-by":"publisher","first-page":"110017","DOI":"10.1016\/j.ejso.2025.110017","volume":"51","author":"Y Liu","year":"2025","unstructured":"Liu Y, Chen Y, Shu J et al (2025) Dual-energy CT for predicting progression-free survival of locally advanced gastric cancer after gastrectomy: insights into tumor angiogenesis. Eur J Surg Oncol 51:110017","journal-title":"Eur J Surg Oncol"},{"key":"11904_CR23","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1007\/s00330-018-5502-3","volume":"28","author":"H-J Kang","year":"2018","unstructured":"Kang H-J, Kim SH, Bae JS, Jeon SK, Han JK (2018) Can quantitative iodine parameters on DECT replace perfusion CT parameters in colorectal cancers? Eur Radiol 28:4775\u20134782","journal-title":"Eur Radiol"},{"key":"11904_CR24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/diagnostics10100814","volume":"10","author":"JJ Xu","year":"2020","unstructured":"Xu JJ, Taudorf M, Ulriksen PS et al (2020) Gastrointestinal applications of iodine quantification using dual-energy CT: a systematic review. Diagnostics 10:814","journal-title":"Diagnostics"},{"key":"11904_CR25","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3748\/wjg.v23.i9.1666","volume":"23","author":"X-H Chen","year":"2017","unstructured":"Chen X-H, Ren K, Liang P, Chai Y-R, Chen K-S, Gao J-B (2017) Spectral computed tomography in advanced gastric cancer: can iodine concentration non-invasively assess angiogenesis? World J Gastroenterol 23:1666\u20131675","journal-title":"World J Gastroenterol"},{"key":"11904_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35712-w","volume":"8","author":"S-M Cheng","year":"2018","unstructured":"Cheng S-M, Ling W, Zhu J, Xu J-R, Wu L-M, Gong H-X (2018) Dual energy spectral CT imaging in the assessment of gastric cancer and cell proliferation: a preliminary study. Sci Rep 8:17619","journal-title":"Sci Rep"},{"key":"11904_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2214\/AJR.20.23528","volume":"216","author":"H Zhao","year":"2021","unstructured":"Zhao H, Li W, Huang W et al (2021) Dual-energy CT-based nomogram for decoding HER2 status in patients with gastric cancer. AJR Am J Roentgenol 216:1539\u20131548","journal-title":"AJR Am J Roentgenol"},{"key":"11904_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13244-023-01490-x","volume":"14","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wang P, Wang B et al (2023) Dual-layer spectral-detector CT for predicting microsatellite instability status and prognosis in locally advanced gastric cancer. Insights Imaging 14:151","journal-title":"Insights Imaging"},{"key":"11904_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(24)00139-9","volume":"403","author":"MA Mansournia","year":"2024","unstructured":"Mansournia MA, Nazemipour M (2024) Recommendations for accurate reporting in medical research statistics. Lancet 403:611\u2013612","journal-title":"Lancet"},{"key":"11904_CR30","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/aje\/kwad139","volume":"192","author":"C Shaw","year":"2023","unstructured":"Shaw C, Wu Y, Zimmerman SC et al (2023) Comparison of imputation strategies for incomplete longitudinal data in life-course epidemiology. Am J Epidemiol 192:2075\u20132084","journal-title":"Am J Epidemiol"},{"key":"11904_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","volume":"25","author":"J Yeong","year":"2022","unstructured":"Yeong J, Lum HYJ, Teo CB et al (2022) Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 25:741\u2013750","journal-title":"Gastric Cancer"},{"key":"11904_CR32","doi-asserted-by":"publisher","unstructured":"Feng Q-X, Zhu Z-N, Li Q, Liu X-S (2024) Dual-energy CT quantitative parameters to evaluate occult peritoneal metastasis in advanced gastric cancer preoperatively. Abdom Radiol (NY) https:\/\/doi.org\/10.1007\/s00261-024-04303-x","DOI":"10.1007\/s00261-024-04303-x"},{"key":"11904_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"11904_CR34","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449\u20131458","journal-title":"Nat Med"},{"key":"11904_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.acra.2022.10.012","volume":"30","author":"W Xie","year":"2023","unstructured":"Xie W, Jiang Z, Zhou X et al (2023) Quantitative radiological features and deep learning for the non-invasive evaluation of programmed death ligand 1 expression levels in gastric cancer patients: a digital biopsy study. Acad Radiol 30:1317\u20131328","journal-title":"Acad Radiol"},{"key":"11904_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01586-2","volume":"11","author":"M Bang","year":"2021","unstructured":"Bang M, Eom J, An C et al (2021) An interpretable multiparametric radiomics model for the diagnosis of schizophrenia using magnetic resonance imaging of the corpus callosum. Transl Psychiatry 11:462","journal-title":"Transl Psychiatry"},{"key":"11904_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13244-017-0571-4","volume":"8","author":"N Rassouli","year":"2017","unstructured":"Rassouli N, Etesami M, Dhanantwari A, Rajiah P (2017) Detector-based spectral CT with a novel dual-layer technology: principles and applications. Insights Imaging 8:589\u2013598","journal-title":"Insights Imaging"},{"key":"11904_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.nic.2017.03.002","volume":"27","author":"R Forghani","year":"2017","unstructured":"Forghani R, De Man B, Gupta R (2017) Dual-energy computed tomography: physical principles, approaches to scanning, usage, and implementation: Part 1. Neuroimaging Clin North Am 27:371\u2013384","journal-title":"Neuroimaging Clin North Am"},{"key":"11904_CR39","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","volume":"24","author":"WQ Sheng","year":"2013","unstructured":"Sheng WQ, Huang D, Ying JM et al (2013) HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 24:2360\u20132364","journal-title":"Ann Oncol"},{"key":"11904_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"11904_CR41","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1007\/s00330-018-5483-2","volume":"28","author":"J Li","year":"2018","unstructured":"Li J, Fang M, Wang R et al (2018) Diagnostic accuracy of dual-energy CT-based nomograms to predict lymph node metastasis in gastric cancer. Eur Radiol 28:5241\u20135249","journal-title":"Eur Radiol"},{"key":"11904_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s00261-024-04200-3","volume":"49","author":"M Xu","year":"2024","unstructured":"Xu M, Ren T, Deng J et al (2024) Correlation of CT parameters and PD-L1 expression status in gastric cancer. Abdom Radiol (NY) 49:1320\u20131329","journal-title":"Abdom Radiol (NY)"},{"key":"11904_CR43","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1007\/s00330-021-07697-0","volume":"31","author":"S Liu","year":"2021","unstructured":"Liu S, Qiao X, Ji C et al (2021) Gastric poorly cohesive carcinoma: differentiation from tubular adenocarcinoma using nomograms based on CT findings in the 40\u2009s late arterial phase. Eur Radiol 31:5768\u20135778","journal-title":"Eur Radiol"},{"key":"11904_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340","journal-title":"Lancet"},{"key":"11904_CR45","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang Y-J et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6:1571\u20131580","journal-title":"JAMA Oncol"},{"key":"11904_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","volume":"16","author":"W Jia","year":"2019","unstructured":"Jia W, Gao Q, Han A, Zhu H, Yu J (2019) The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med 16:655\u2013670","journal-title":"Cancer Biol Med"},{"key":"11904_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006454","volume":"11","author":"J Jung","year":"2023","unstructured":"Jung J, Heo YJ, Park S (2023) High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer 11:e006454","journal-title":"J Immunother Cancer"},{"key":"11904_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13244-023-01459-w","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhao S, Wu Z et al (2023) Virtual biopsy using CT radiomics for evaluation of disagreement in pathology between endoscopic biopsy and postoperative specimens in patients with gastric cancer: a dual-energy CT generalizability study. Insights Imaging 14:118","journal-title":"Insights Imaging"},{"key":"11904_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13244-022-01361-x","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H, Liang P, Yong L et al (2023) Development and external validation of a radiomics model for assessment of HER2 positivity in men and women presenting with gastric cancer. Insights Imaging 14:20","journal-title":"Insights Imaging"},{"key":"11904_CR50","doi-asserted-by":"publisher","unstructured":"Lin X, Xu S, Wang Y et al (2025) Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-11601-5","DOI":"10.1007\/s00330-025-11601-5"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11904-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11904-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11904-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:09:05Z","timestamp":1772446145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11904-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["11904"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11904-7","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Jianbo Gao.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Q.y.-J. received funding from the Natural Science Foundation of Inner Mongolia Autonomous Region (2021MS08005). J.L. received funding from the National Natural Science Foundation of China (82202146), Henan Provincial Medical Science and Technology Project (SBGJ202402030), and Science and Technology Development Foundation of Henan Province (242102311173). L.F.L. is affiliated with Siemens Healthineers. X.Z.C. is\u00a0affiliated with\u00a0Deepwise Inc..\u00a0Other authors declare that they have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Participants in the prospective study (Registration number, ChiCTR2400082707) provided informed consent, while the need for informed consent for the retrospective study was waived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Ethical approval was obtained from the Institutional Review Board of all participating hospitals.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}